Work

Supplementary Table 4 from Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Year: 2023

Type: supplementary-materials

Abstract: CTC v3.0 toxicities grade 3 or higher for patients in the No-GO and GO cohorts treated on AAML03P1 and AAML0531.

DOI: 10.1158/1078-0432.22460757.v1

Authors: Katherine Tarlock, Todd A. Alonzo, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Lillian Sung, Jessica A. Pollard, Richard Aplenc, Michael R. Loken, Alan S. Gamis, Soheil Meshinchi

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361919763

Cites:

Cited by:

Related to: 10